Navigation Links
ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Date:9/1/2015

EDISON, N.J., Sept. 1, 2015 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Rodman & Renshaw 17th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. taking place September 8-10, 2015 at The St. Regis Hotel in New York, NY.

James Sapirstein, Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:Rodman & Renshaw 17th Annual Global Investment ConferenceDate: Thursday, September 10, 2015Time: 3:00pm (Eastern Time)Location:The St. Regis Hotel, New York, NYThe presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the investor relations section of the ContraVir website at www.contravir.com/ctrv.

About ContraVir Pharmaceuticals ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®), for the Hepatitis B virus (HBV) in Phase 2 clinical studies.  CMX157 is active against HBV and more than 4 times more potent in vitro versus tenofovir.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  

For further information, please contact:Tiberend Strategic Advisors, Inc.

Tirth Patel (investors) 
tpatel@tiberend.com; (212) 375-2681

Claire Sojda (media) 
csojda@tiberend.com; (212) 375-2686

 

 

 


'/>"/>
SOURCE ContraVir Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. ContraVir to Present at Cavendish Global Health Impact Forum
2. MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations
3. Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting
4. VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015
5. Asterias Biotherapeutics to Present at Upcoming Investor Conferences
6. Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease
7. Roka Bioscience to Present at the Sidoti & Company Emerging Growth Conference
8. Forge Therapeutics Co-Founder to Present at the 250th American Chemical Society National Meeting
9. Asymmetrex Presents Its Crowdsourcing Campaign for Counting Adult Tissue Stem Cells at the 8th International Epigenetics, Stem Cells, Sequencing & SNiPs Meeting in August
10. Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
11. United Therapeutics Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... WORTH, Texas (PRWEB) , ... August 13, 2019 ... ... Fort Collins, Colorado to focus on prepackaged mobile phases for QC laboratories. After ... reinvent Chata from its laboratory sciences approach into a valued supplier of manufacturing ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... microbiome populations down to the strain level, has announced partnerships with six international ... products to companies and research organizations in Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, ...
(Date:7/30/2019)... ... July 30, 2019 , ... The summer season ... events company. Not only has the company already hosted many of its signature ... Parties to its guests. , With Lajollacooks4u’s Private Cooking Parties, guests prepare and ...
(Date:7/19/2019)... ... July 18, 2019 , ... World renowned ... be joining forces with California-based charity Coalition Duchenne for its 9th Annual Expedition ... raises awareness and funding for Duchenne muscular dystrophy and was founded by Sabahan ...
Breaking Biology Technology:
(Date:8/1/2019)... ORLANDO, Fla. (PRWEB) , ... August 01, 2019 , ... ... at the point of care. It is fully developed with over 100 units ... with applications into new fields of use, our collaboration with axiVEND will give us ...
(Date:8/1/2019)... ... ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice President of ... with the upcoming EU MDR IVDR regulations . , Jay is ... positions over his 26 years at the FDA, including developing the framework and authoring ...
(Date:7/23/2019)... (PRWEB) , ... July 22, 2019 , ... Personalized Stem ... a New Drug (IND) application for use of a person’s own adipose-derived stem cells ... stem cells as a treatment of osteoarthritis in the knee. , This ...
Breaking Biology News(10 mins):